Aripiprazole
Drugpill, 2,5-20 mg/day, maximum 16 weeks
NCT Number: NCT01119014
The benefits and harms of antipsychotics are relatively well studied in adults. However, there is a lack of scientifically valid studies regarding the benefits and harms of antipsychotics in children and adolescents with psychosis.
The main objective of the TEA trial is to compare the efficacy and adverse reactions of two antipsychotics (quetiapine versus aripiprazole) in children and adolescents between 12-17 years of age with psychotic symptoms on psychopathology, cognitive deficits, and daily functioning. Furthermore, the trial will focus on adverse reaction profiles of the two antipsychotics as well as early predictors of later sustained clinical effects of these antipsychotics.
Looking for future studies?
Notify Me12 year–17 year
All sexes
Interventional
Phase 4
Aalborg Psychiatric Hospital, Aalborg, Denmark
A sex and age matched healthy control group will be included to form a reference group for cognitive and somatic measures. The healthy controls will not receive any trial medication.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Patients - Inclusion Criteria:
Patients - Exclusion Criteria:
Healthy volunteers - Inclusion Criteria:
Healthy volunteers - Exclusion Criteria:
pill, 2,5-20 mg/day, maximum 16 weeks
pill, 50-600mg/day, maximum 16 weeks
Time frame: 12 weeks
Time frame: 12 weeks
Psychopathology (other PANSS scales, DIPI, SGI-S, CGI-I,and GAPD).
Time frame: 12 weeks
Cognition and functioning (BACS Global Score, SCoRS-DK, Schizophrenia Cognition Rating Scale, BRIEF)
Time frame: 12 weeks
Adverse reactions (UKU side effect scale, AIMS, SAS, BARS, and other adverse events)
Time frame: 12 weeks
Suicidal ideation (K-SADS-PL, specific questions for depressive disorders (current)
Time frame: 12 weeks
Genetic variants affecting metabolism of antipsychotics
Time frame: 12 weeks
Prognostic factors (DUP, and PAS)
Time frame: 52 weeks
Quality of Life (measured with Kidscreen)
Time frame: 52 weeks
Qualitative interviews
Anne Katrine Pagsberg
Other
Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis- An Investigator-initiated, Phase IV, Randomised Double-blind Multi-centre Trial of the Benefits and Harms of Aripiprazole Versus Quetiapine in Children and Adolescents With Psychosis
Acronym: TEA
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05808244
Mental Disorders, Psychosis
Kowloon, Hong Kong
View Trial DetailsNCT07364825
Anxiety, Anxiety Disorders
Belmont, Massachusetts, United States
View Trial DetailsNCT04004416
Bipolar Disorder, Bipolar and Related Disorders
Ann Arbor, Michigan, United States
View Trial DetailsNCT05863572
Mental Disorders, Psychosis
Kampala, Uganda
View Trial Details